First National Bank of Omaha Takes $6.60 Million Position in AbbVie Inc. $ABBV

First National Bank of Omaha acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV) during the 3rd quarter, HoldingsChannel.com reports. The fund acquired 28,484 shares of the company’s stock, valued at approximately $6,595,000.

Several other hedge funds also recently modified their holdings of the business. Evolution Wealth Management Inc. acquired a new position in AbbVie during the second quarter worth $26,000. Spurstone Advisory Services LLC acquired a new stake in shares of AbbVie in the second quarter worth about $28,000. Financial Gravity Companies Inc. bought a new stake in shares of AbbVie during the 2nd quarter worth about $36,000. Delos Wealth Advisors LLC acquired a new position in shares of AbbVie during the 2nd quarter valued at about $39,000. Finally, Abich Financial Wealth Management LLC acquired a new position in shares of AbbVie during the 3rd quarter valued at about $49,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ABBV. HSBC raised AbbVie from a “hold” rating to a “buy” rating and upped their target price for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a report on Tuesday, January 20th. BMO Capital Markets reiterated an “outperform” rating and issued a $258.00 target price on shares of AbbVie in a research note on Thursday, January 15th. Citigroup decreased their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a report on Tuesday, January 27th. Finally, Raymond James Financial set a $256.00 price objective on AbbVie in a research note on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $251.56.

AbbVie Stock Up 0.5%

Shares of ABBV opened at $232.69 on Wednesday. The stock’s 50-day moving average price is $223.93 and its 200 day moving average price is $221.63. The firm has a market capitalization of $411.25 billion, a price-to-earnings ratio of 98.60, a P/E/G ratio of 0.81 and a beta of 0.35. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.AbbVie’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.